INTRODUCTION
============

Left bundle branch block (LBBB) is a marker of poor prognosis in heart failure (HF) patients, and interest in LBBB is increasing due to the development of cardiac-resynchronization therapy (CRT).[@B1][@B2][@B3][@B4][@B5] Among the randomized population included in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) trial, LBBB patients without left axis deviation (LAD) appeared to receive a greater benefit from CRT than did those with LAD.[@B6] The most common cause of LAD is left anterior fascicular block (LAFB), but LAFB cannot explain the LAD in patients with complete LBBB.[@B7][@B8][@B9] The proposed mechanisms of LAD in patients with LBBB include attitudinal changes in the anatomy such as a cardiomegaly and changes in myocyte mass.[@B10] A previous study showed that patients with LBBB with LAD had greater incidence of cardiomegaly, HF, advanced conduction disease, cardiovascular mortality, and major adverse cardiac event than those with a normal axis.[@B11][@B12] Another study indicated that LBBB with LAD does not confer a significant mortality risk, but those with a normal axis who developed LAD during the study period had a significantly higher mortality.[@B13] However, limited data is available regarding the prognostic significance of LAD in acute heart failure syndrome (AHFS) patients with LBBB. Therefore, the aim of the present study is to determine the association between LAD and the clinical outcomes of AHFS with LBBB.

METHODS
=======

Study population
----------------

The Korean Acute Heart Failure (KorAHF) registry is a prospective multicenter cohort. Between January 2011 and February 2014, a total of 5,625 patients, who were hospitalized due to AHFS were consecutively enrolled from 10 university hospitals. The patients are planned for follow-up until 2018. Patients who had signs or symptoms of HF and one of the following criteria were eligible for the study: 1) lung congestion or 2) objective findings of LV systolic dysfunction or structural heart disease. Lung congestion was defined as 'congestion' on a chest X-ray or as rales on physical examination. Electrocardiograms (ECGs) were recorded at a standard paper speed of 25 mm/s and calibration of 10 mm/mV. They were read by trained physicians who were blinded to clinical data, site interpretation, and patient outcomes. LBBB was defined by the following criteria: 1) QRS duration \>120 ms, 2) broad notched or slurred R waves in leads I, aVL, V5, and V6, and an occasional RS pattern in V5 and V6 attributed to a displaced transition of the QRS complex, 3) absent Q waves in leads I, V5, and V6 or a narrow Q wave in lead aVL, in the absence of a myocardial pathology, and 4) a peak R time greater than 60 ms in leads V5 and V6 but normal in leads V1, V2, and V3 when small initial r waves could be discerned in the above leads.[@B14] Among the registered study population, 1,168 (20.8%) patients had QRS prolongation (\>120 ms). Among these population, 292 patients presented with LBBB, 344 patients with intra-ventricular conduction delay (IVCD), 398 patients with RBBB, and 134 with pacing rhythm ([Figure 1](#F1){ref-type="fig"}). We included patients with LBBB for analysis in the present study. The Institutional Review Board of each hospital approved the study protocol.
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Data collection
---------------

Detailed information on the study design and results from interim analysis are described in our previous paper.[@B15][@B16] In brief, the investigators completed a web-based case report form at enrollment and at each visit in the Clinical Data Management System (iCReaT) from the Korea National Institute of Health. The latest information on patient clinical manifestation, laboratory results, and medications was collected at admission, at discharge, and during follow-up (30 days, 3 months, 6 months, and 1 to 5 years annually). In-hospital mortality and the cause of death were adjudicated by an independent event committee. The mortality data for patients who were lost to follow-up was collected from National Insurance data or National Death Records.

Definitions and outcomes
------------------------

LAD was defined as a QRS axis \<−30 degree in accordance with published criteria.[@B14] Echocardiography was available for 96.6% (282/292) of the study population and left ventricular ejection fraction (LVEF) was assessed by the biplane Simpson technique, M-mode, or visual estimation.[@B17] To evaluate the right ventricle (RV) dilatation on the surface ECG, any combination of at least 2 of 3 electrocardiographic criteria (late R in lead aVR, low voltages in the limb leads, and R/S ratio \<1 in lead V~5~) was used.[@B18]

The AHFS patients with LBBB were divided into 2 groups according to QRS axis (\<−30 or ≥−30 degree). The primary end point was death from any cause. The secondary end points were reduced LVEF and RV dilatation.

Statistical analysis
--------------------

Continuous variables were examined using Student\'s t-test or Wilcoxon rank-sum test when applicable. Categorical data were compared using the χ^2^ test or Fisher\'s exact test, as appropriate. The event-free survival was assessed by Kaplan-Meier analyses and the significance level was evaluated with the log-rank test. In multivariate Cox regression models for the survivors, covariates that were suggested to be relevant on univariate analysis with p value \<0.2 or clinically relevant were considered as candidate variables. Adjusted hazard ratios (HRs) were compared by Cox regression based on age, sex, ischemic etiology, hypertension, diabetes mellitus, LVEF \<40%, body mass index ≥25 kg/m^2^, QRS duration ≥150 ms, and creatinine ≥2 mg/dL. To assess the association between the QRS axis and echocardiographic parameters, including LVEF, E/A ratio, E/e′, deceleration time, left atrial size, and right ventricular systolic pressure, a locally weighted scatterplot smoothing (LOESS) method was utilized. To determine the predictors of LVEF, a multiple linear regression analysis was used. The variables for analysis were selected by the same criteria depicted in the Cox regression model, except LVEF \<40%. Statistical analyses were performed using R Statistical Software (version 3.1.3; R Foundation for Statistical Computing, Vienna, Austria) with a p\<0.05 considered statistically significant.

RESULTS
=======

Baseline characteristics of the study population
------------------------------------------------

The median (interquartile range) age of the 292 patients was 75 (68--80) years, and 46.6% were males. Patients with de novo HF accounted for 40.8% of the total, and 37.7% of the study population were classified as having ischemic cardiomyopathy. Among the study population, 80.8% of the patients were in sinus rhythm and 18.5% were in atrial fibrillation or flutter. The mean values of QRS duration and LVEF were 155.7 ms and 28.4%, respectively.

Among the study population, 189 (64.7%) patients had a normal axis, and 103 (35.3%) had LAD. The baseline clinical characteristics, treatment strategy, laboratory data, and outcomes on admission according to the presence of LAD are described in [Table 1](#T1){ref-type="table"}. Compared to the normal axis group, the LAD group had a higher proportion of males and a lower proportion of patients with diabetes mellitus. Also, the patients with LAD had a significantly higher creatinine level, lower body mass index, and lower LVEF values. The other variables did not significantly differ between the 2 groups.

###### Baseline clinical characteristics according to the presence of LAD
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                                   No LAD (n=189)              LAD (n=103)           p value                  
  -------------------------------- --------------------------- --------------------- ------------ ----------- -------
  Age (years)                      72.6±10.8                   74.0±11.7             0.29                     
  Male                             79 (41.8)                   57 (55.3)             0.04                     
  Alcohol                          63 (33.3)                   39 (37.9)             0.52                     
  Current smoker                   24 (12.7)                   14 (13.6)             0.97                     
  Body mass index (kg/m^2^)        23.5±3.5                    22.0±3.5              0.001                    
  Hypertension                     105 (55.6)                  68 (66.0)             0.11                     
  Diabetes mellitus                89 (47.1)                   34 (33.0)             0.03                     
  Chronic kidney disease           26 (13.8)                   18 (17.5)             0.50                     
  Cerebrovascular accident         20 (10.6)                   17 (16.5)             0.20                     
  Pulmonary disease                20 (10.6)                   18 (17.5)             0.14                     
  De-novo heart failure            83 (43.9)                   36 (35.0)             0.17                     
  Ischemic etiology                79 (41.8)                   31 (30.1)             0.07                     
  NYHA classification                                                                0.24                     
                                   2                           19 (10.1)             17 (16.5)                
                                   3                           71 (37.6)             39 (37.9)                
                                   4                           99 (52.4)             47 (45.6)                
  Systolic blood pressure (mmHg)   127.4±25.5                  128.3±27.9            0.80                     
  Heart rate (beats/min)           93.6±21.9                   90.4±24.5             0.25                     
  Treatment                                                                                                   
                                   Beta blocker at discharge   103 (54.5)            55 (53.4)    0.95        
                                   RAS blockade at discharge   138 (73.0)            78 (75.7)    0.72        
                                   AA at discharge             105 (55.6)            50 (48.5)    0.31        
                                   Mechanical ventilation      30 (15.9)             20 (19.4)    0.55        
  Laboratory data                                                                                             
                                   QRS axis                    21.3±34.8             −49.8±12.3   \<0.001     
                                   Rhythm                                                         0.50        
                                                               Sinus rhythm          152 (80.4)   84 (81.6)   
                                                               Atrial fibrillation   31 (16.4)    18 (17.5)   
                                                               Miscellaneous         6 (3.2)      1 (1.0)     
                                   PR interval (ms)            169.6±38.7            175.5±39.1   0.26        
                                   QRS duration (ms)           154.1±17.6            158.3±21.2   0.09        
                                                               LVEF (%)              29.6±10.0    26.1±9.8    0.006
                                                               Na (mg/dL)            137.5±4.7    137.4±4.6   0.77
                                                               Creatinine (mg/dL)    1.3±0.8      1.7±1.5     0.01
  Outcomes on admission                                                                                       
                                   In-hospital mortality       9 (4.8)               3 (2.9)      0.65        
                                   ICU admission               95 (50.3)             52 (50.5)    \>0.99      
                                   Hospital days               9 (6--15)             9 (6--15)    0.89        

Data are presented as the mean±standard deviation, number (%) or median (interquartile range).

AA = aldosterone antagonist; ICU = intensive care unit; LAD = left axis deviation; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; PCI = percutaneous coronary intervention; RAS = renin angiotensin system.

Clinical outcome
----------------

The median follow-up duration was 24 months (interquartile range, 12--35). There was a total of 123 (42.1%) all-cause deaths during the follow-up period. On univariate analysis, the patients with LAD did not have a significantly higher all-cause mortality compared to those with no LAD (LAD group vs. no LAD group, 46.6% vs. 39.7%, unadjusted HR, 1.17; 95% confidence interval \[CI\], 0.81, 1.68; p=0.40, [Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}). Even after adjusting for the clinically relevant and statistically significant variables, multivariate analysis did not show any significant difference between the 2 groups (adjusted HR, 1.01; 95% CI, 0.66, 1.53; p=0.97, [Table 2](#T2){ref-type="table"}).

###### Multivariate Cox regression analysis for predictors of all-cause mortality
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  Variables                     Unadjusted HR (95% CI)   p value   Adjusted HR^\*^ (95% CI)   p value
  ----------------------------- ------------------------ --------- -------------------------- ---------
  LAD                           1.17 (0.81, 1.68)        0.40      1.01 (0.66, 1.53)          0.97
  Age                           1.04 (1.02, 1.06)        \<0.001   1.05 (1.02, 1.07)          \<0.001
  Male                          1.39 (0.97, 1.98)        0.07      1.36 (0.92, 2.02)          0.12
  Ischemic etiology             1.90 (1.33, 2.70)        \<0.001   1.65 (1.10, 2.48)          0.02
  Hypertension                  1.30 (0.90, 1.88)        0.16      0.98 (0.65, 1.49)          0.94
  Diabetes mellitus             1.10 (0.77, 1.58)        0.59      0.80 (0.53, 1.18)          0.26
  LVEF \<40%                    1.01 (0.60, 1.69)        0.97      1.30 (0.76, 2.22)          0.33
  Body mass index ≥25 kg/m^2^   1.09 (0.72, 1.66)        0.67      1.06 (0.67, 1.67)          0.82
  QRS duration ≥150 ms          0.94 (0.65, 1.35)        0.73      0.82 (0.55, 1.22)          0.33
  Creatinine ≥2 mg/dL           3.05 (2.05, 4.55)        \<0.001   3.12 (1.98, 4.93)          \<0.001

CI = confidence interval; HR = hazard ratio; LAD = left axis deviation; LVEF = left ventricular ejection fraction.

^\*^C-index of the Cox regression model was 0.687 (95% CI, 0.630, 0.744).

![Kaplan-Meier curves of AHFS patients with LBBB according to the presence of LAD. Kaplan-Meier curve of all-cause death for AHFS patients with LBBB in the no LAD group (blue line) versus the LAD group (red line).\
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Predictors of the echocardiographic parameters
----------------------------------------------

To determine the impact of the QRS axis on the echocardiographic parameters, an LOESS method was performed. The LOESS model results of the echocardiographic parameters are depicted in [Figure 3](#F3){ref-type="fig"}. In [Figure 3A](#F3){ref-type="fig"}, the LVEF peaked at 0 degrees of the QRS axis and trended downward when the axis was increased or decreased. After dividing the patients into 3 groups (QRS axis \<−30, −30 to 90, and \>90 degree), simple linear regression showed that the LAD was a significant predictor of a worse LVEF (adjusted coefficient, −3.03, 95% CI, −5.53, −0.52, p=0.02) ([Table 3](#T3){ref-type="table"}). The significant association between LAD and a worse LVEF was maintained on multiple linear regression analysis (adjusted coefficient, −3.25; 95% CI, −5.82, −0.67; p=0.01) ([Table 3](#T3){ref-type="table"}). Although the E/A ratio, LA size, and right ventricular systolic pressure appeared to vary as the QRS axis changed, as shown in [Figure 3B](#F3){ref-type="fig"}, [3E](#F3){ref-type="fig"}, and [3F](#F3){ref-type="fig"}, there was no significant difference among the 3 groups.

![LOESS curves of the echocardiographic parameters according to the QRS axis. LOESS curves of the LVEF (A), E/A ratio (B), E/e′ (C), DT (D), LA size (E), and RVSP (F) according to the QRS axis.\
DT = deceleration time; LA = left atrium; LOESS = locally weighted scatterplot smoothing; LVEF = left ventricular ejection fraction; RVSP = right ventricular systolic pressure.](kcj-48-1002-g003){#F3}

###### Multiple linear regression analysis for the predictors of lower LVEF
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  Variables                     Unadjusted slope (95% CI)   p value                Adjusted slope (95% CI)   p value                
  ----------------------------- --------------------------- ---------------------- ------------------------- ---------------------- ------
  Normal QRS axis (reference)                                                                                                       
                                LAD                         −3.03 (−5.53, −0.52)   0.02                      −3.25 (−5.82, −0.67)   0.01
                                RAD                         0.45 (−9.47, 10.36)    0.93                      −0.20 (−10.08, 9.67)   0.97
  Age                           0.18 (0.07, 0.28)           0.001                  0.16 (0.04, 0.27)         0.007                  
  Male                          −1.31 (−3.69, 1.07)         0.28                   −0.56 (−3.00, 1.87)       0.65                   
  Ischemic etiology             2.00 (−0.44, 4.44)          0.11                   0.69 (−1.88, 3.26)        0.60                   
  Hypertension                  2.30 (0.90, 1.88)           0.16                   0.98 (0.65, 1.49)         0.94                   
  Diabetes mellitus             2.64 (0.23, 5.06)           0.03                   1.57 (−1.08, 4.22)        0.24                   
  Body mass index ≥25 kg/m^2^   0.98 (−1.83, 3.78)          0.49                   0.89 (−1.97, 3.75)        0.54                   
  QRS duration ≥150 ms          −0.26 (−2.73, 2.22)         0.84                   −0.26 (−2.73, 2.22)       0.83                   
  Creatinine ≥2 mg/dL           1.67 (−1.58, 4.91)          0.31                   1.29 (−1.98, 4.57)        0.44                   

CI = confidence interval; LAD = left axis deviation; LVEF = left ventricular ejection fraction; RAD = right axis deviation.

RV dilatation
-------------

There was a significantly higher proportion of RV dilatation criteria in the LAD group compared to the no LAD group (LAD vs. no LAD, 40.8% vs. 12.7%, p\<0.001). In particular, a late R in aVR was the strongest contributing factor (51.5% vs. 6.3%, p\<0.001).

To evaluate the impact of RV dilatation criteria of the surface ECG on all-cause mortality, a Kaplan-Meier method with log-rank test was performed. In [Figure 4](#F4){ref-type="fig"}, the Kaplan-Meier curve for all-cause death based on RV dilatation criteria showed that there was no significant difference in all-cause mortality between the 2 groups (log-rank p=0.751).

![Kaplan-Meier curve of all-cause death in AHFS patients with LBBB according to RV dilatation criteria. Kaplan-Meier curve of all-cause death in AHFS patients with LBBB in the no RV dilatation group (blue line) versus RV dilatation group (red line).\
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DISCUSSION
==========

In this study, the prognostic significance of LAD in patients who had AHFS with LBBB was investigated using a prospective multicenter cohort registry. There were several main findings of our study. 1) Among the AHFS patients with LBBB, the presence of LAD did not predict all-cause mortality. 2) The LVEF was significantly lower in AHFS patients with LBBB and LAD than in those without LAD. 3) LAD was a significant predictor of RV dilatation, which was evaluated by surface ECG criteria in patients with AHFS and LBBB.

The prognostic significance of LAD in patients with LBBB has been controversial in various study populations. In chronic LBBB patients, the presence of LAD has been shown to confer greater incidence of cardiomegaly, myocardial dysfunction, advanced conduction disease, and cardiovascular mortality.[@B11][@B19] Also, in patients with HF and LBBB who undergo successful implantations of CRT devices, the presence of LAD suggests a poor clinical outcome, including all-cause mortality and HF re-hospitalizations or events.[@B6][@B20] Park et al.[@B12] recently reported that LAD is associated with myocardial scarring and major adverse cardiac event in patients with LBBB. On the other hand, in patients with HF and LBBB who undergo ICD implantations, LAD does not predict all-cause mortality or HF events.[@B6] In addition, for LBBB patients who undergo an ECG for any reason, LAD does not confer a significant mortality risk.[@B13] Our study showed that LAD was not a significant predictor of all-cause mortality in an AHFS cohort. To the best of our knowledge, this is the first study to confirm the prognostic significance of LAD on clinical outcomes in AHFS patients with LBBB. It was estimated that the cause of the discrepancy between our data and the data of HF patients who underwent CRT implantations was due to the differences in the study populations and differences in the benefit of CRT based on the presence of LAD. Also, we speculated that the prognostic impact of LAD had little significance in a high-risk study population, such as those with AHFS and LBBB, because they already exhibit multiple poor prognostic factors and mortality risks.

A previous study showed that the presence of LAD in LBBB patients does not signify a further decrease in LVEF.[@B21] However, the present study demonstrated that LVEF is significantly lower in AHFS patients who have LBBB with LAD than in those without LAD. Also, patients with LAD in the present study had a significantly higher proportion of RV dilatation than did those without LAD. These results support that the main cause of LAD in patients with LBBB is anatomical change, such as cardiomegaly or myocardial scarring resulting from previous study.[@B10][@B22][@B23] Moreover, lower LVEF seen in the LAD group may be the cause or be a result of LAD. Further physiological or pathological studies are needed to evaluate the mechanism of LAD in LBBB patients.

Impaired RV function is an established marker of poor prognosis in patients with moderate to severe HF.[@B24][@B25] However, our data showed that the all-cause mortality rate did not significantly differ between those who did or did not satisfy the RV dilatation criteria. Although numerous studies have been performed to evaluate the impact of RV dysfunction on clinical outcomes and CRT benefit, this issue remains controversial.[@B26][@B27][@B28] An additional larger prospective cohort study is needed to evaluate the association between RV dysfunction and CRT benefit or mortality.

This study had several limitations. First, the current hypothesis was not defined prior to conducting the registry, and a relatively small study population was included in the final analysis, as the present study population consisted of a subgroup of the KorAHF registry. Second, it was an observational study, which may have affected the results because of confounding factors. Third, although the portion of missing data was small, 3.4% of the study population did not have echocardiographic data including that of the LVEF. Finally, due to the limitations of our data-base, we did not have any information on the RV parameters from the echocardiographic data or new onset LAD from the follow-up ECG.

Among AHFS patients with LBBB, the presence of LAD did not predict all-cause mortality, but it can be used as a significant predictor of worse LVEF and RV dilatation.
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